Tempero Bio
Tempero Bio is a clinical-stage biopharmaceutical company developing TMP-301, an investigational therapy targeting relapse prevention in substance use disorders. Founded in 2020 and headquartered in Oakland, California, the firm operates pre-revenue with a single paused Phase 2 asset.
- Company typePrivate
- Founded2020
- HeadquartersOakland, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tempero Bio does
Tempero Bio is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Oakland, California (incorporated in Delaware). The company develops investigational therapies for Substance Use Disorders, with its sole clinical asset being TMP-301, a therapy targeting relapse prevention in addiction treatment. TMP-301 was advancing through Phase 2 clinical trials for alcohol use disorder before the program was paused in 2025, with the company now evaluating further options for the candidate. The company maintains a strategic/co-development relationship with Nxera (formerly Sosei Group) related to the TMP-301 program.
The company operates as a pre-revenue, venture-backed private biotechnology firm. It is led by founder Ricardo Dolmetsch and backed by biotech-focused investor Aditum Bio alongside Khosla Ventures and 8VC. In March 2025, Tempero Bio closed a $70 million Series B financing (with 8VC leading) intended to fund Phase 2 trials of TMP-301, and also filed an SEC Form D for an exempt securities offering of approximately $76.96 million. The firm's planned revenue model relies on eventual commercialization of approved therapies through licensing agreements, co-promotion partnerships, or direct sales upon regulatory approval.
Tempero Bio currently has 1-10 employees and operates with no commercialized products, no disclosed revenue, and a single-asset pipeline. The company primarily engages in scientific publications, clinical trial announcements, and investor relations communications as its go-to-market activities, consistent with traditional early-stage biotech commercialization pathways. Following the Phase 2 program pause, the company's near-term strategic direction hinges on how it repositions TMP-301 or its pipeline.
Tempero Bio firmographics
Firmographics- Name
- Tempero Bio
- Legal name
- Tempero Bio, Inc.
- Website
- https://temperobio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Tempero Bio is a clinical-stage biopharmaceutical company developing TMP-301, an investigational therapy targeting relapse prevention in substance use disorders. Founded in 2020 and headquartered in Oakland, California, the firm operates pre-revenue with a single paused Phase 2 asset.
- Ownership category
- akta.pro rank
Tempero Bio industry classification
Industry- Product category
- Substance Use Disorder Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)
Keywords
Where Tempero Bio is headquartered
LocationHeadquarters
- HQ city
- Oakland
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Tempero Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Therapeutic Development and Commercialization: Pre-revenue biotech company developing pharmaceutical therapeutic for substance use disorders. Revenue will be generated through eventual commercialization of approved drug therapies, likely via licensing agreements, co-promotion partnerships, or direct sales upon regulatory approval.
Go-to-market motion1 record
Marketing channels2 records
Tempero Bio product offering
Product offeringCore offering
Tempero Bio is developing TMP-301, an investigational small-molecule therapeutic for substance use disorders that targets relapse prevention in addiction treatment. The drug candidate was being advanced through Phase 2 clinical trials for alcohol use disorder before the program was paused in 2025 while the company evaluates further options. The company is pre-revenue and intends to commercialize through licensing or partnership with established pharmaceutical companies upon regulatory approval.
Product overview
Tempero Bio is a Delaware-based biotechnology company developing a single product pipeline focused on TMP-301, an investigational therapy for substance use disorders. The company's primary offering is a drug candidate targeting relapse prevention in addiction treatment, which was advancing through Phase 2 clinical trials before the program was paused.
Differentiator
Problem solved
Functional benefit
Products and services
- TMP-301
Companies that use Tempero Bio
Customer profileSegments1 record
Ideal customer profiles2 records
Tempero Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Tempero Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Nxera (formerly Sosei Group)coreNxera (formerly Sosei Group) is a strategic partner related to Tempero Bio's TMP-301 program. The partnership was referenced in the context of Nxera's third-quarter earnings results, indicating a financial or operational relationship in the development of the alcohol use disorder candidate TMP-301. Tempero Bio has paused its Phase 2 program for TMP-301 and is evaluating further options, as reported through Nxera's earnings disclosure.
Scale indicators3 records
Recent moves5 records
Expansion highlights3 records
Tempero Bio competitors and assessment
Company assessmentDirect peers
- Alkermes: Alkermes develops and commercializes CNS therapeutics including Vivitrol (naltrexone) for alcohol and opioid use disorder. It is the most directly comparable specialty biopharma focused on long-acting treatments for SUD.
- Indivior: Indivior is a global specialty pharmaceutical company focused on opioid use disorder (Suboxone, Sublocade). It is a direct peer in the substance use disorder therapeutics market with similar regulatory and commercialization dynamics.
Emerging players
- Adial Pharmaceuticals: Adial Pharmaceuticals is developing AD04, a serotonergic therapy for alcohol use disorder. Comparable as a small clinical-stage biotech pursuing a novel mechanism for AUD relapse reduction.
- Mind Medicine (MindMed): MindMed is a clinical-stage psychedelic medicine company developing therapies for addiction and mental health. Comparable as a small public biotech pursuing novel CNS mechanisms in SUD.
- Tonix Pharmaceuticals: Tonix is a clinical-stage CNS-focused biopharma developing therapeutics across neurology, psychiatry, and addiction. Comparable in stage and therapeutic area focus on CNS drug development.
- BioXcel Therapeutics: BioXcel Therapeutics is a clinical-stage biotech using AI-driven drug discovery for immuno-oncology and neuroscience. Comparable as a small clinical-stage company pursuing CNS indications with innovative mechanisms.
- atai Life Sciences: atai Life Sciences is a clinical-stage biopharma developing psychedelic and other novel therapies for mental health, including addiction. Comparable in therapeutic area and clinical-stage CNS pipeline approach.
- Cybin: Cybin is a clinical-stage psychedelics company targeting mental health and addiction disorders. Comparable as a small clinical-stage company pursuing novel CNS mechanisms for SUD.
Broad incumbents
- Pfizer: Pfizer is a major pharmaceutical incumbent with a broad CNS and addiction portfolio historically and significant resources to acquire or in-license specialty CNS assets like Tempero's.
- Johnson & Johnson: J&J Innovative Medicine has a strong addiction portfolio including Sublocade-competitor therapies (via Janssen historical assets) and significant M&A capacity in CNS/addiction therapeutics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Tempero Bio social profiles
Digital presenceTempero Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tempero Bio leadership team
Management profileNumber of profiles
Profiles1 record
Tempero Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tempero Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tempero Bio
What does Tempero Bio do?
Tempero Bio is developing TMP-301, an investigational small-molecule therapeutic for substance use disorders that targets relapse prevention in addiction treatment. The drug candidate was being advanced through Phase 2 clinical trials for alcohol use disorder before the program was paused in 2025 while the company evaluates further options. The company is pre-revenue and intends to commercialize through licensing or partnership with established pharmaceutical companies upon regulatory approval.
Is Tempero Bio a public or private company?
Tempero Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Tempero Bio founded?
Tempero Bio was founded in 2020. It employs 1 to 10 people.
Where is Tempero Bio based?
Tempero Bio is headquartered in Oakland, United States, in the North America region.
How does Tempero Bio make money?
One revenue line is on record: therapeutic Development and Commercialization.
Who are Tempero Bio's main competitors?
Direct peers on record are Alkermes and Indivior. Emerging players are Adial Pharmaceuticals, Mind Medicine (MindMed), Tonix Pharmaceuticals, BioXcel Therapeutics, atai Life Sciences and Cybin. Broad incumbents are Pfizer and Johnson & Johnson.
Does Tempero Bio have an API?
No public API is recorded for Tempero Bio.
What industry is Tempero Bio in?
Tempero Bio's product category is Substance Use Disorder Therapeutics. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 541714 and its SIC code is 2834.